Elamipretide (SS-31): A Course on What the Published Literature Reports

Elamipretide, widely referred to in preclinical papers by its research code SS-31 (and historically MTP-131 or Bendavia), is one of the most extensively studied mitochondria-targeted peptides in the published literature. This course-style page walks through what the peer-reviewed record describes: the molecule itself, the mechanism researchers have proposed, the clinical programmes that have been run, the regulatory milestone recorded in 2026, and the adverse events reported in trials. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question, symptom or treatment decision.

Module 1: What Elamipretide Is

A 2025 review in the International Journal of Molecular Sciences described elamipretide as a short, water-soluble, mitochondria-targeted tetrapeptide with an alternating aromatic-cationic structure that allows it to cross cell membranes and accumulate on the inner mitochondrial membrane (PMID 39940712). That same review reported that the peptide's accumulation is not dependent on the mitochondrial membrane potential, which distinguishes it from many other mitochondria-directed molecules that rely on charge gradients to concentrate inside the organelle (PMID 39940712).

Because elamipretide is a peptide, it is not orally absorbed in a conventional way, and the clinical literature has used parenteral administration. The 168-week open-label extension of the TAZPOWER study in Barth syndrome, for example, reported that participants received elamipretide 40 mg once daily by subcutaneous injection (PMID 38602181). Doses used in other indications are not reproduced here unless the verified literature summarised on this page states them.

Naming conventions to know

• SS-31 — the designation used in most cell and animal work, including studies of its mitochondrial protein interactions (PMID 32554501).
• Elamipretide — the international nonproprietary name used in clinical trials and regulatory documents (PMID 41335372).
• Szeto–Schiller (SS) peptides — the broader chemical family from which SS-31 was developed, described in mechanistic reviews (PMID 39940712).

Module 2: The Proposed Mechanism

The mechanism most often cited in the literature centres on cardiolipin, a phospholipid unique to the inner mitochondrial membrane that helps shape cristae and organise the respiratory supercomplexes. The 2025 structural and mechanistic review reported that elamipretide associates with cardiolipin, stabilises cristae architecture, supports electron transport chain efficiency and reduces excessive reactive oxygen species production (PMID 39940712).

A 2020 study in PNAS extended that picture by mapping the mitochondrial protein interaction landscape of SS-31 using photoaffinity labelling; the researchers reported that the peptide interacted with a defined set of inner-membrane proteins involved in ATP production and metabolite transport, and that these interactions depended on the presence of cardiolipin (PMID 32554501). That study is frequently cited as evidence that the peptide behaves less like a conventional antioxidant and more like a membrane-interface modulator.

A 2022 review in Heart Failure Reviews framed the same mechanism in the context of cardiac disease, reporting that mitochondrial dysfunction — impaired bioenergetics, cristae disorganisation and oxidative stress — is a shared feature of heart failure phenotypes, and that elamipretide was developed to address that shared feature rather than a single disease pathway (PMID 35037146).

Module 3: Regulatory Status

A 2026 Drugs article titled "Elamipretide: First Approval" documented the peptide's transition from investigational agent to approved medicine for Barth syndrome, a rare X-linked disorder of cardiolipin remodelling (PMID 41335372). That same article summarised the development history across multiple mitochondrial indications and the ongoing programmes that had not reached approval (PMID 41335372).

Two points follow from that status for anyone reading the literature. First, an approval in one rare indication does not extend to the other conditions in which the peptide has been studied. Second, material sold outside a regulated pharmaceutical supply chain — including vials labelled "research use only" — is not the same product studied in the trials described below, and the published record contains no evaluation of such material. A 2026 Sports Medicine review of approved and unapproved peptide therapies for musculoskeletal injury and athletic performance reported that many peptides circulating in that space lack controlled human efficacy data and that safety information is often incomplete (PMID 41966639).

Module 4: Barth Syndrome — The Most Mature Clinical Dataset

Barth syndrome is caused by TAFAZZIN variants that disrupt cardiolipin remodelling, producing cardiomyopathy, skeletal myopathy, neutropenia and growth delay. Because the defect sits directly on the cardiolipin pathway, it became the lead indication for a cardiolipin-associating peptide.

The TAZPOWER programme began as a randomised, double-blind, placebo-controlled crossover trial and continued as an open-label extension. The 2024 report of the 168-week open-label extension described long-term efficacy and safety outcomes in participants who received elamipretide 40 mg daily by subcutaneous injection, with researchers reporting improvements from baseline on functional and patient-reported measures sustained over the extension period (PMID 38602181). The study was small — Barth syndrome affects a very small population — and open-label extensions lack a concurrent placebo group, both of which the authors treated as interpretive limits (PMID 38602181).

The 2026 first-approval review placed this dataset in context, reporting that the Barth syndrome evidence base formed the basis of the regulatory decision (PMID 41335372).

Module 5: Primary Mitochondrial Myopathy and the RePOWER Registry

Primary mitochondrial myopathy (PMM) covers a heterogeneous group of genetic disorders in which muscle bioenergetics fail. Trial design in PMM is difficult: the phenotypes vary, outcome measures are not standardised, and natural history data are sparse.

RePOWER was designed to address that gap. The 2026 report described RePOWER as an international, prospective, non-interventional registry that characterised patients with primary mitochondrial myopathy, capturing genotype, symptom burden and functional status without assigning any treatment (PMID 40785393). Registries such as this one do not test a drug; researchers use them to define populations, select endpoints and interpret later interventional results (PMID 40785393). The 2025 mechanistic review listed primary mitochondrial myopathy among the indications in which elamipretide has been investigated (PMID 39940712).

Module 6: Heart Failure

Cardiac muscle is among the most mitochondria-dense tissues in the body, which made heart failure an early target. The 2022 Heart Failure Reviews article summarised preclinical and clinical work with elamipretide across heart failure with reduced and preserved ejection fraction, reporting that mitochondrial bioenergetic deficits are a consistent feature of failing myocardium and that the peptide was investigated as a way to target that deficit directly (PMID 35037146). The same review discussed why translation from animal models to clinical endpoints has been challenging in this field (PMID 35037146).

At the cellular level, a 2025 study in Biomedicine & Pharmacotherapy examined a mitochondria-targeted construct combining SS-31 with the ferroptosis inhibitor ferrostatin-1 in cardiomyocytes subjected to hypoxia/reoxygenation, and the researchers reported that the targeted delivery approach alleviated markers of ferroptosis in that model (PMID 39848110). That work is a cell-culture study of a novel conjugate, not a trial of elamipretide in patients.

Module 7: Ophthalmology and Retinal Disease

Photoreceptors and retinal pigment epithelium are highly energy-dependent, and mitochondrial decline has been implicated in age-related macular degeneration (AMD). A 2021 review in Cells surveying potential therapeutic candidates for AMD included mitochondria-targeted approaches among the strategies under investigation for dry AMD and geographic atrophy (PMID 34572131).

Delivery is a central obstacle in retinal pharmacology. A 2025 review in Expert Opinion on Pharmacotherapy examined delivery systems reshaping retinal disease management — including sustained-release implants, gene-based approaches and alternatives to repeated intravitreal injection — and reported that delivery route, not just molecular mechanism, determines whether a candidate can be evaluated meaningfully in the eye (PMID 40319468).

Module 8: Preclinical Neuroscience and Vascular Ageing

Beyond muscle, heart and retina, SS-31 appears in a wide preclinical literature. A 2019 study in the Journal of Neuroinflammation examined SS-31 in mice given lipopolysaccharide, and the researchers reported that the peptide improved measures of mitochondrial dysfunction and attenuated the synaptic and memory impairment induced by the inflammatory challenge (PMID 31747905). Findings in rodent neuroinflammation models have not been shown to predict cognitive outcomes in humans.

In the vascular ageing field, a 2026 GeroScience study reported that mitochondrial dysfunction drives age-related degeneration of the thoracic aorta, linking bioenergetic failure in vascular tissue to structural deterioration with age (PMID 41233677). That study explains why mitochondria-targeted peptides are of interest in geroscience, but it is a mechanistic animal-model investigation rather than a clinical trial (PMID 41233677).

Module 9: Elamipretide Adverse Events: What Studies Report

The clearest human safety information in the verified literature comes from the long-term Barth syndrome extension. The 168-week open-label extension report described the safety profile of daily subcutaneous elamipretide over the extension period, with injection-site reactions featuring among the adverse events reported by participants receiving daily subcutaneous dosing (PMID 38602181). Local reactions at the injection site are a recurring theme in daily-injection peptide programmes generally.

The 2026 first-approval review summarised the tolerability data that accompanied the regulatory decision alongside the efficacy data (PMID 41335372). Broader reviews of peptide therapeutics have emphasised that safety data for peptides outside approved indications are frequently incomplete, and that unregulated products carry additional risks of contamination and mislabelling (PMID 41966639).

Important caveats when reading safety data on this compound:

• The study populations were small and highly selected, particularly in a rare disease such as Barth syndrome (PMID 38602181).
• Open-label extensions enrol participants who tolerated the drug in the preceding blinded phase, which can understate adverse-event rates (PMID 38602181).
• No verified study on this page evaluated elamipretide in healthy adults for performance, longevity or cosmetic purposes.

Module 10: Reading the Evidence Map

Three habits for interpreting this literature

1. Separate species and setting. A cardiomyocyte culture study of an SS-31 conjugate under hypoxia/reoxygenation answers a different question than a multi-year human extension study (PMID 39848110, PMID 38602181).
2. Check whether a paper tested the drug at all. Registries and reviews describe populations and summarise prior work rather than generating new efficacy data (PMID 40785393).
3. Distinguish approval from generalisation. The 2026 review documented approval in a single rare cardiolipin-remodelling disorder, not a broad mitochondrial indication (PMID 41335372).

Module 11: Open Questions in the Literature

Several questions remain unresolved in the published record. Whether cardiolipin-targeted stabilisation translates into durable clinical benefit outside disorders of cardiolipin remodelling has not been established; the 2022 heart failure review discussed this translational gap explicitly (PMID 35037146). Endpoint selection in primary mitochondrial myopathy remains an active methodological problem, which is part of why prospective registries were built (PMID 40785393). In ophthalmology, delivery route remains a limiting factor for any systemically administered candidate aimed at the posterior segment (PMID 40319468). And in the wider peptide space, reviewers have reported that marketing claims often outrun the controlled evidence (PMID 41966639).

Anyone following this compound can track those questions by watching for randomised, adequately powered trials with pre-specified functional endpoints, and by noting whether new publications report on the approved product or on a laboratory analogue such as an SS-31 conjugate (PMID 39848110).

Again, this material is educational summary only and is not medical advice; medical questions about mitochondrial disease, cardiomyopathy or retinal disease belong with a licensed physician.

References

• Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential (International Journal of Molecular Sciences, 2025)
• Elamipretide: First Approval (Drugs, 2026)
• Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER (Genetics in Medicine, 2024)
• RePOWER: An International, Prospective, Non-Interventional Registry of Patients With Primary Mitochondrial Myopathy (Clinical Genetics, 2026)
• Targeting mitochondrial dysfunction with elamipretide (Heart Failure Reviews, 2022)
• Mitochondrial protein interaction landscape of SS-31 (PNAS, 2020)
• Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice (Journal of Neuroinflammation, 2019)
• SS-31@Fer-1 Alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes via mitochondrial targeting (Biomedicine & Pharmacotherapy, 2025)
• Potential Therapeutic Candidates for Age-Related Macular Degeneration (AMD) (Cells, 2021)
• Beyond the injection: delivery systems reshaping retinal disease management (Expert Opinion on Pharmacotherapy, 2025)
• Mitochondrial dysfunction drives age-related degeneration of the thoracic aorta (GeroScience, 2026)
• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Sports Medicine, 2026)